Ryan Cassaday, MD
Enriched profileProfessor, Division of Hematology and Oncology, University of Washington · University of Washington
Ryan Cassaday is Professor, Division of Hematology and Oncology, University of Washington at University of Washington. OpenAlex indexes 343 publications with 7,332 citations (h-index 39); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 25 Oct 2026
Ryan Cassaday, M.D., is Professor, Division of Hematology and Oncology, University of Washington. The public record shows 343 publications with 7,332 citations (h-index 39), centered on CAR-T cell therapy research, Acute Lymphoblastic Leukemia research, Lymphoma Diagnosis and Treatment. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 11 companies.
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: CAR-T cell therapy research
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 25 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 34 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 89.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 25 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Sponsor: University of Washington
Industry payments
Updated 25 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Autolus IncProgram year20254 payments
- PFIZER INC.Program year20251 payment
- SERVIER PHARMACEUTICALS LLCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
71.4%Corticosteroid42.9%Prednisone100%Part D<11 patientsBile Acid28.6%Ursodiol100%Part D<11 patientsDermatology
28.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor28.6%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 25 Oct 2026
103 congress contributions (2006–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL).
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 25 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)- 01
- 02The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasisArticle706 citations2004
- 03
- 04
- 05
Network
Updated 25 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 25 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ryan-cassaday-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
fredhutch.org/en/faculty-lab-directory/cassaday-ryan.html
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fredhutch.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 25 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Wisconsin School of Medicine and Public Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Editorial & leadership roles
journal and society appointments- Member
NCCN Guidelines Panel for Acute Lymphoblastic Leukemia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →education.binaytara.org ↗
Secondary affiliations
appointments beyond the home institution- Professor
Clinical Research Division, Fred Hutch Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hemonc.uw.edu ↗
Media & interviews
press, podcasts and appearances- Oncology Insights with Dr. Petros Grivas
Episode 19 (Fred Hutch, August 2026): discussion of recent advances in acute lymphoblastic leukemia treatment
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Rainer Storb
University of Washington
Connie Celum, MD, MPH
University of Washington
Helen Chu, MD, MPH
University of Washington
Bryan Kestenbaum, MD
University of Washington
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center